19 New Decacorns in 2026 – The US Has Never Seen This Before
19 US startups crossed $10B through July, according to PitchBook data, already surpassing 2025's full-year total of 18 and on track to beat the 2021 record of 22 before the year is out. There are now 63 active decacorns in the US, up from 53 last year and 26 in 2021. The rate at which companies are crossing the $10 billion threshold has more than doubled in four years.
Who Is Crossing the Line
The 2026 decacorn class is dominated by AI. SambaNova Systems, a chip manufacturer specialising in AI inference, crossed the threshold when it raised $1 billion in a Series F led by General Atlantic at an $11 billion valuation. Other new members of the class include Shield AI, Cerebras, Clear Street, ElevenLabs, Harvey, and Notion, alongside the companies that have been on a trajectory toward the line for most of the year.
Three new decacorns in July in the same month, the three new decacorns in a single 30-day period adding $49 billion in combined value. July also saw 40 companies joined the unicorn board, led by fintech, robotics, and AI.
The sector spread is wider than 2021. The 2021 decacorn wave was concentrated in consumer software and fintech. The 2026 class spans AI inference hardware (SambaNova, Cerebras), defence AI (Shield AI), legal AI (Harvey), voice AI (ElevenLabs), and financial infrastructure (Clear Street), spreading across more categories than the headline AI concentration figures suggest.
Why Companies Are Staying Private Longer
The decacorn boom is partly a function of companies choosing to stay private rather than list. late-stage founders are delaying IPOs, with at least one client valued above $10 billion that had IPO plans ready in Q1 but paused when conditions shifted.
The structural incentive to stay private has strengthened over the past two years. Tender offers now let employees and early investors sell shares without waiting for an IPO, removing one of the traditional forcing mechanisms that pushed companies toward public markets. Secondary markets are growing and we covered the record $121 billion in H1 2026 secondary volume in our piece on the secondaries market. Companies that generate ample revenue and face no immediate pressure from LPs or employee liquidity have genuine optionality on timing that earlier generations did not have.
The counterpart is that not all decacorns are in the same position. Some are still pre-revenue. Colossal Biosciences is reportedly raising new funding at a valuation north of $20 billion despite being years from any commercial product. A $10 billion valuation covers a wide range of business models and financial realities, and the headline number alone tells you less than it used to.
What This Means for the Exit Backlog
The growth in active US decacorns from 26 in 2021 to 63 today reflects the same dynamic we covered in our piece on the 2021 vintage DPI crisis: companies that raised at peak valuations have stayed private rather than face down-round IPO pricing, and the backlog of value waiting to transfer to public markets has grown alongside them.
Mega-deals accounted for 87.5%, which means the capital creating new decacorns is concentrated at the top of the market. The companies crossing $10 billion are the ones absorbing most of the available capital, while the middle of the distribution competes for a shrinking share. That concentration creates the conditions for a handful of large exits to define returns for an entire vintage, which is exactly what the exit backlog data shows.
63 active US decacorns, most of them AI companies choosing to stay private because they can, represent an enormous amount of unrealised value sitting in private portfolios, and the timing of how that value transfers to public markets will set private market returns for years.
NonPublic Pty Ltd (ABN 49 607 216 928) holds Australian Financial Services Licence #482668. Investments are available to wholesale and sophisticated investors as defined under the Corporations Act 2001. This content is general in nature and does not constitute financial product advice. It does not take into account your objectives, financial situation, or needs. Investing in private markets involves significant risk, including the potential loss of your entire investment. Past performance is not a reliable indicator of future results. You should obtain independent financial advice before making any investment decision.
